Lisdexamfetamin Orion Pharma: Uses, Dosage & Side Effects

What Is Lisdexamfetamin Orion Pharma and What Is It Used For?

Lisdexamfetamin Orion Pharma contains the active substance lisdexamfetamine dimesylate, a therapeutically inactive prodrug that is specifically designed to be converted into its pharmacologically active metabolite, dexamphetamine (d-amphetamine), after oral administration. Unlike conventional amphetamine formulations that deliver the active drug directly, lisdexamfetamine consists of the amino acid L-lysine covalently bonded to dexamphetamine. This chemical bond must be enzymatically cleaved in the body before the active drug is released, providing a unique pharmacological profile that distinguishes it from other stimulant medications used in ADHD management.

After ingestion, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and enters the systemic circulation. The conversion to dexamphetamine occurs primarily through rate-limited enzymatic hydrolysis by enzymes in red blood cells. This rate-limited conversion is a critical pharmacological feature: because the body can only convert lisdexamfetamine to dexamphetamine at a controlled rate, the resulting plasma concentrations of dexamphetamine rise gradually rather than spiking rapidly. This produces a smooth onset of therapeutic effect, a sustained duration of action lasting approximately 13 to 14 hours, and a gradual decline that reduces the risk of rebound symptoms at the end of the dosing interval.

Dexamphetamine, the active metabolite of lisdexamfetamine, exerts its therapeutic effects through multiple mechanisms in the central nervous system. It primarily increases the synaptic availability of two key neurotransmitters: norepinephrine (noradrenaline) and dopamine. Dexamphetamine achieves this by (1) promoting the release of these catecholamines from presynaptic nerve terminals, (2) inhibiting their reuptake through blockade of the dopamine transporter (DAT) and norepinephrine transporter (NET), and (3) to a lesser extent, inhibiting the enzymatic degradation of catecholamines by monoamine oxidase (MAO). The net result is enhanced catecholaminergic neurotransmission in brain regions that are critically involved in attention, executive function, and impulse control, including the prefrontal cortex, striatum, and nucleus accumbens.

ADHD is a neurodevelopmental disorder characterised by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning and development. It affects approximately 5–7% of children and 2.5–4% of adults worldwide, making it one of the most common psychiatric conditions. Current neuroscientific understanding suggests that ADHD involves dysfunction in catecholaminergic circuits, particularly dopaminergic and noradrenergic pathways in the prefrontal cortex and associated brain networks. By enhancing neurotransmission in these circuits, stimulant medications like lisdexamfetamine help to normalise brain function and improve the core symptoms of ADHD.

Lisdexamfetamine is indicated for the treatment of ADHD in children aged 6 years and older, adolescents, and adults as part of a comprehensive treatment programme. This comprehensive approach typically includes psychological measures (such as cognitive behavioural therapy), educational accommodations, and social support, alongside pharmacotherapy. Treatment should only be initiated by a physician with expertise in the management of ADHD, such as a paediatrician, child and adolescent psychiatrist, or adult psychiatrist. A thorough diagnostic assessment is required before starting treatment, and the diagnosis should be made according to established criteria such as those in the DSM-5 or ICD-11.

The clinical efficacy of lisdexamfetamine in ADHD has been extensively demonstrated in multiple randomised, double-blind, placebo-controlled clinical trials across all age groups. In children and adolescents, pivotal studies have shown that lisdexamfetamine significantly improves ADHD symptom scores as measured by validated rating scales such as the ADHD Rating Scale IV (ADHD-RS-IV), with effect sizes that are among the highest of any ADHD medication. In adults, clinical trials have demonstrated similar efficacy, with significant improvements in attention, impulsivity, and hyperactivity symptoms compared to placebo. Long-term studies extending up to 12 months have confirmed sustained efficacy without evidence of tolerance development at therapeutic doses.

What Should You Know Before Taking Lisdexamfetamin Orion Pharma?

Contraindications

Lisdexamfetamine must not be used in several clearly defined clinical situations. The most important absolute contraindications include hypersensitivity to lisdexamfetamine dimesylate, dexamphetamine, other sympathomimetic amines, or any of the excipients in the formulation. Additionally, lisdexamfetamine is contraindicated in patients with known cardiovascular disease, including structural cardiac abnormalities, cardiomyopathy, serious heart rhythm disturbances, coronary artery disease, and heart failure. These contraindications exist because amphetamines increase heart rate and blood pressure, which could be dangerous in patients with pre-existing cardiovascular conditions.

Other important contraindications include moderate to severe hypertension that is uncontrolled, hyperthyroidism or thyrotoxicosis, agitated states or patients with a history of significant anxiety or tension, current or recent (within the last 14 days) use of monoamine oxidase inhibitors (MAOIs) due to the risk of hypertensive crisis, known drug or alcohol dependence, a history of cerebrovascular disorders (stroke, cerebral aneurysm, vascular abnormalities), pheochromocytoma, and advanced arteriosclerosis. Lisdexamfetamine should also not be used in patients with a diagnosis of anorexia nervosa or bulimia nervosa, nor in those with glaucoma.

Warnings and Precautions

Cardiovascular safety is of paramount importance with any stimulant medication. Amphetamines, including the dexamphetamine released from lisdexamfetamine, cause a modest average increase in resting heart rate (typically 2–6 beats per minute) and blood pressure (systolic increase of approximately 2–4 mmHg, diastolic increase of approximately 1–3 mmHg). While these changes are generally not clinically significant in healthy individuals, they can be important in patients with pre-existing cardiovascular conditions. Sudden death has been reported in association with CNS stimulant treatment at usual doses in patients with structural cardiac abnormalities or other serious heart problems. Therefore, a comprehensive cardiovascular assessment is mandatory before initiating treatment.

Psychiatric adverse effects should also be carefully considered. Stimulant medications can potentially exacerbate pre-existing psychotic or manic symptoms and, in rare cases, may cause new-onset psychotic or manic symptoms in patients without a prior history. Patients should be monitored for the emergence or worsening of aggressive behaviour, hostility, anxiety, depression, and suicidal ideation. If new psychiatric symptoms develop, the benefit of continuing treatment should be reassessed. Lisdexamfetamine should be used with caution in patients with a history of bipolar disorder, as stimulants may trigger manic episodes.

Growth monitoring is essential in children and adolescents receiving lisdexamfetamine. Stimulant medications have been associated with decreased appetite and weight loss, which may lead to reduced growth velocity (height and weight) in some patients. While most studies suggest that final adult height is generally not significantly affected, regular monitoring of height, weight, and appetite is recommended throughout treatment. If growth suppression is observed, the physician may consider temporarily interrupting treatment (such as during school holidays) or adjusting the dose.

Pregnancy and Breastfeeding

Lisdexamfetamine should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the possible risks to the developing foetus. Animal reproduction studies with amphetamines have shown potential adverse effects, including evidence of embryotoxicity and increased perinatal mortality at high doses. In humans, use of amphetamines during pregnancy has been associated with potential risks including premature birth, low birth weight, and neonatal withdrawal symptoms (such as agitation, feeding difficulties, and excessive drowsiness). Women of childbearing potential should use effective contraception during treatment. If a patient becomes pregnant while taking lisdexamfetamine, the treatment should be reassessed and the risks and benefits discussed with the treating physician.

Amphetamines, including dexamphetamine, are excreted in human breast milk. Breastfeeding is not recommended during treatment with lisdexamfetamine due to the potential for adverse effects in the breastfed infant, including reduced feeding, insomnia, and weight loss. The decision to discontinue breastfeeding or to discontinue the drug should take into account the importance of the drug to the mother and the potential risks to the infant.

Driving and Operating Machinery

Lisdexamfetamine may affect the ability to drive and operate machinery, particularly during the initial phase of treatment and after dose adjustments. While stimulant medications can improve concentration and alertness in patients with ADHD, they can also cause side effects such as dizziness, drowsiness, visual disturbances, or fatigue in some individuals. Patients should be cautioned about the potential impact on their ability to drive or use machines and should be advised not to engage in these activities until they know how lisdexamfetamine affects them. It is also important to note that in many jurisdictions, driving while taking amphetamine-based medications may have specific legal implications, and patients should be informed of the relevant regulations in their country.

How Does Lisdexamfetamin Orion Pharma Interact with Other Drugs?

Unlike many newer biological medications that have minimal drug interactions, lisdexamfetamine and its active metabolite dexamphetamine have several clinically significant interactions that must be carefully considered. Dexamphetamine affects multiple neurotransmitter systems, is partially metabolised by cytochrome P450 enzymes (particularly CYP2D6), and its renal elimination is pH-dependent. These pharmacological properties create the potential for meaningful interactions with a range of commonly prescribed medications.

The most dangerous interaction is with monoamine oxidase inhibitors (MAOIs). MAOIs prevent the enzymatic breakdown of catecholamines, and when combined with the catecholamine-releasing effects of amphetamines, the result can be a sudden and severe hypertensive crisis, potentially leading to intracranial haemorrhage, stroke, or death. For this reason, lisdexamfetamine must not be used during treatment with MAOIs or within 14 days of discontinuing an MAOI. This contraindication applies to all types of MAOIs, including irreversible non-selective inhibitors (such as phenelzine and tranylcypromine), reversible MAO-A inhibitors (such as moclobemide), and the MAO-B inhibitor selegiline (which at higher doses also inhibits MAO-A).

Serotonergic drug interactions also warrant careful attention. Amphetamines can increase serotonergic neurotransmission, and when combined with other serotonergic medications, there is a theoretical risk of serotonin syndrome, a potentially life-threatening condition characterised by agitation, confusion, rapid heart rate, hyperthermia, muscle rigidity, and seizures. Medications that require caution include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans, lithium, tramadol, tryptophan, and St John’s wort. While the absolute risk is low, patients should be monitored for signs and symptoms of serotonin syndrome when these combinations are used.

In addition to the interactions listed above, patients should be aware that amphetamines can interact with anaesthetic agents. If surgery requiring general anaesthesia is planned, the prescribing physician and anaesthetist should be informed about lisdexamfetamine use, as there is a potential for interactions with certain anaesthetic drugs and a risk of acute hypertensive episodes. Some authorities recommend discontinuing stimulant medications on the day of surgery, though this should be discussed with the treating physician on a case-by-case basis.

Alcohol consumption should be approached with caution during lisdexamfetamine treatment. While there is no direct pharmacokinetic interaction, amphetamines can mask the sedative effects of alcohol, potentially leading to increased alcohol consumption and greater risk of alcohol-related harm. Patients should be advised to limit alcohol intake and be aware that their perception of intoxication may be altered.

What Is the Correct Dosage of Lisdexamfetamin Orion Pharma?

Lisdexamfetamine should always be taken exactly as prescribed by your doctor. The dose is individualised according to the therapeutic needs and response of each patient. Treatment should be initiated at the lowest effective dose and titrated upwards gradually. The goal of dose titration is to find the dose that provides optimal symptom control with the fewest side effects. Throughout treatment, the dose should be periodically reassessed, and the physician should consider dose reductions or treatment interruptions to evaluate the patient’s ongoing need for the medication.

Adults

Children and Adolescents

In children aged 6 to 12 years, treatment is usually initiated at a dose of 20 or 30 mg once daily in the morning. The dose is adjusted in increments of 10 to 20 mg at approximately weekly intervals until an optimal response is achieved. The maximum recommended dose is 70 mg per day. In adolescents aged 13 to 17 years, the dosing approach is similar to that in adults, with a starting dose of 30 mg once daily and titration in increments of 20 mg at weekly intervals up to a maximum of 70 mg per day. Height and weight should be monitored regularly, and treatment holidays (e.g., during school holidays) may be considered if growth suppression is observed.

Elderly Patients

There are limited clinical data on the use of lisdexamfetamine in patients aged 65 years and older. Elderly patients may have an increased sensitivity to sympathomimetic amines and are more likely to have concurrent cardiovascular conditions. If treatment is considered in this age group, it should be initiated at the lowest available dose (20 mg) with cautious upward titration and close monitoring of cardiovascular parameters. The pharmacokinetics of dexamphetamine may be altered in elderly patients due to age-related changes in renal function, body composition, and hepatic metabolism.

How to Take the Capsules

Lisdexamfetamine capsules should be taken once daily in the morning, with or without food. Taking the capsule in the morning helps to minimise the risk of insomnia, as the duration of action extends approximately 13 to 14 hours. The capsule should be swallowed whole with water. Alternatively, for patients who have difficulty swallowing capsules (such as young children), the capsule may be opened and the entire contents dissolved in a glass of water, orange juice, or yoghurt. The entire mixture should be consumed immediately; it should not be stored for later use. The powder inside the capsule should not be divided into smaller doses, as this may affect the accuracy of dosing.

Missed Dose

If you miss a dose of lisdexamfetamine, take it as soon as you remember, provided it is still early enough in the day. Because lisdexamfetamine has a long duration of action, taking it later in the day (typically after midday or early afternoon) may interfere with sleep. If it is too late in the day, skip the missed dose and take the next dose at the regular time the following morning. Do not take a double dose to make up for a missed one.

Overdose

The prodrug design of lisdexamfetamine provides an inherent safety advantage in the context of overdose. Because the conversion to dexamphetamine is rate-limited by enzymatic capacity in red blood cells, even large oral doses of lisdexamfetamine do not produce the same rapid peak in dexamphetamine levels that would occur with an equivalent dose of immediate-release dexamphetamine. However, at sufficiently high doses, the enzymatic capacity can still be overwhelmed, and any overdose should be treated as a medical emergency. Contact your local poison control centre or emergency department immediately if an overdose is suspected.

What Are the Side Effects of Lisdexamfetamin Orion Pharma?

Like all medicines, lisdexamfetamine can cause side effects, although not everybody gets them. The side effects of lisdexamfetamine are predominantly related to the pharmacological action of its active metabolite, dexamphetamine, on the sympathetic nervous system and central nervous system. Many side effects are dose-dependent and tend to be most prominent during the initial weeks of treatment or following dose increases. Most common side effects are mild to moderate in severity and often diminish with continued treatment as the body adjusts to the medication.

Understanding the frequency and nature of potential side effects is essential for informed decision-making about treatment. The frequency categories used below follow standard medical convention: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people).

Decreased appetite is the most frequently reported side effect and is particularly important to manage in children and adolescents, where it can lead to clinically meaningful weight loss and growth suppression. Strategies for managing appetite loss include taking the medication with or after breakfast, providing calorie-dense foods when the child is hungry (often in the evening after the medication effect has waned), and monitoring growth parameters regularly. Some physicians recommend treatment holidays during school vacations to allow catch-up growth.

Insomnia is another very common side effect that often improves with dose optimisation and sleep hygiene measures. Taking lisdexamfetamine early in the morning (ideally before 9:00 AM) can help minimise its impact on sleep. Establishing a consistent bedtime routine, avoiding screens before sleep, and reducing caffeine intake are additional strategies that can help. If insomnia persists despite these measures, the physician may consider dose reduction or the short-term use of melatonin as an adjunct.

Cardiovascular effects, including increased heart rate and blood pressure, are expected pharmacological effects of amphetamines. In most patients, these changes are mild and clinically insignificant. However, in rare cases, more serious cardiovascular events have been reported, including arrhythmias, myocardial infarction, and stroke. These events are extremely rare at therapeutic doses and occur almost exclusively in patients with pre-existing cardiovascular risk factors. Regular monitoring of vital signs is recommended, with particular attention at each dose adjustment and at intervals of no more than 6 months during maintenance therapy.

How Should You Store Lisdexamfetamin Orion Pharma?

Proper storage of lisdexamfetamine is important for maintaining the medication’s stability and potency, as well as for ensuring safety. The capsules should be stored at room temperature, not exceeding 25°C (77°F). They should be kept in the original container or blister pack to protect from moisture and light. Do not store lisdexamfetamine in the bathroom or in areas of high humidity, as moisture can degrade the medication. Do not freeze the capsules.

Keep lisdexamfetamine out of the sight and reach of children and adolescents who are not prescribed the medication. Because lisdexamfetamine is a controlled substance with a potential for misuse, it is particularly important to store it securely, ideally in a locked cabinet or other secure location. This helps to prevent accidental ingestion by young children and reduces the risk of diversion or unauthorized use.

Do not use the medication after the expiry date stated on the packaging. The expiry date refers to the last day of the indicated month. If you have any unused or expired capsules, do not dispose of them in household waste or via wastewater. Return any unused medication to your pharmacy for safe disposal in accordance with local environmental regulations. This helps to protect the environment and prevent accidental exposure.

If you have opened a capsule and dissolved the contents in water, orange juice, or yoghurt, the mixture should be consumed immediately. Do not store prepared solutions for later use, as the stability of dissolved lisdexamfetamine in these media has not been established beyond immediate consumption.

What Does Lisdexamfetamin Orion Pharma Contain?

The active ingredient in Lisdexamfetamin Orion Pharma is lisdexamfetamine dimesylate. Lisdexamfetamine dimesylate is the mesylate salt of lisdexamfetamine, a prodrug consisting of the amino acid L-lysine conjugated to dexamphetamine. Each capsule contains a precisely measured amount of lisdexamfetamine dimesylate corresponding to the strength indicated on the packaging. The available strengths are 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg, with the dose referring to the amount of lisdexamfetamine dimesylate (not the equivalent amount of dexamphetamine).

The capsules contain several inactive ingredients (excipients) that serve important pharmaceutical functions. Microcrystalline cellulose is used as a filler and binder to ensure consistent capsule content. Croscarmellose sodium acts as a disintegrant, helping the capsule contents to break apart and dissolve rapidly after ingestion. Magnesium stearate is used as a lubricant during the manufacturing process to ensure smooth capsule filling.

The hard capsule shell is typically composed of gelatin, along with one or more colouring agents that differ according to the capsule strength, allowing easy identification of different doses. Common colouring agents used in the capsule shells may include titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172), and indigo carmine (E132), depending on the specific strength. The capsule shells may also contain sodium lauryl sulfate and may be imprinted with pharmaceutical-grade edible ink for identification purposes.

Lisdexamfetamin Orion Pharma does not contain lactose, gluten, or sucrose. Patients with known allergies or intolerances to any of the listed excipients should inform their healthcare provider before starting treatment. The detailed composition of each capsule strength can be found in the patient information leaflet supplied with the medication or obtained from the pharmacist.